Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV
APExBIO - Vorapaxar|PAR-1 antagonist,potent and orally active|CAS# 618385-01-6
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet
Vorapaxar | CAS:618385-01-6 | PAR-1 antagonist,potent and orally active | High Purity | Manufacturer BioCrick
Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com
Chemical structure of vorapaxar. | Download Scientific Diagram
![Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC](https://www.trc-canada.com/prod-img/V758202.png "Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC")
Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC
Vorapaxar - an overview | ScienceDirect Topics
Vorapaxar - Wikipedia
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
Vorapaxar - Wikipedia
Vorapaxar | Uses, Brand Names, Mechanism Of Action
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
The net clinical benefit of vorapaxar (CV death, MI, stroke or GUSTO... | Download Scientific Diagram
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Vorapaxar sulfate (SCH 530348 sulfate) | PAR-1 Antagonist | MedChemExpress
IJMS | Free Full-Text | Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Vorapaxar - wikidoc
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download
